IL2 and melanoma: Among 27 patients treated with adoptive T-cell therapy (ACT) for stage IV melanoma after failing prior immunotherapies (i.e., anti-CTLA-4 and/or intravenous IL-2), higher predicted neoantigen and mutational loads were associated with clinical benefit.